Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:25:22.514Z.
Calculation as of: 2026-10-06T13:25:22.514Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$867.60M
EV/EBITDA Ratio
N/A
TTM Avg
45.75x
3Y Avg
45.75x
5Y Avg
45.75x
Market Cap
$819.44M
EV/EBITDA Ratio
N/A
TTM Avg
76.03x
3Y Avg
57.10x
5Y Avg
57.10x
Market Cap
$786.48M
EV/EBITDA Ratio
N/A
TTM Avg
316.20x
3Y Avg
225.87x
5Y Avg
225.87x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | N/A | 7.99x | 7.99x | 7.99x |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 45.75x | 45.75x | 45.75x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | N/A | 76.03x | 57.10x | 57.10x |
| InMode Ltd. (INMD)vs › | $812.20M | 6.02x | 7.11x | 8.26x | 13.78x |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 316.20x | 225.87x | 225.87x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
